| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	Needham analyst Mike Matson maintains OrthoPediatrics (NASDAQ:KIDS) with a Buy and lowers the price target from $42 to $26.
																	BTIG analyst Ryan Zimmerman reiterates OrthoPediatrics (NASDAQ:KIDS) with a Buy and maintains $23 price target.
																	
																	OrthoPediatrics (NASDAQ:KIDS) affirms FY2025 sales outlook from $233.500 million-$234.500 million to $233.500 million-$234.500 ...
																	OrthoPediatrics (NASDAQ:KIDS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.2...
																	OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS), a company focused exclusively on adv...
																	
																	Lake Street analyst Ben Haynor maintains OrthoPediatrics (NASDAQ:KIDS) with a Buy and lowers the price target from $37 to $34.